FASENRA▼ benralizumab

FASENRA is indicated as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting β-agonists.1

References

  1. FASENRA Summary of Product Characteristics. January 2018. Available from:https://www.medicines.org.uk/emc/product/8918 .
  2. Tan LD, Bratt JM, Godor D, et al. J Asthma Allergy. 2016;9:71–81.
  3. Kolbeck R, Kozhich A, Koike M, et al. J Allergy Clin Immunol. 2010;125(6):1344–53.e2.
  4. Laviolette M, Gossage DL, Gauvreau G, et al. J Allergy Clin Immunol. 2013;132:1086–96.
  5. Bleecker ER, FitzGerald JM, Chanez P, et al. Lancet. 2016;388:2115–27. 
  6. Bleecker ER, FitzGerald JM, Chanez P, et al. Lancet. 2016;388:2115–27. APPENDIX. Available from: http://www.sciencedirect.com/science/article/pii/S0140673616313241?via%3Dihub (accessed March 2018)
  7. Nair P, Wenzel S, Rabe K, et al. N Engl J Med. 2017; 376:2448–58.
  8. Nair P, Wenzel S, Rabe K, et al. N Engl J Med. 2017;376:2448–58. APPENDIX. Available from: http://www.nejm.org/doi/suppl/10.1056/NEJMoa1703501/suppl_file/nejmoa1703501_appendix.pdf (accessed March 2018).
  9. FitzGerald JM, Bleecker ER, Nair P, et al. Lancet. 2016;388:2128–41.
  10. FitzGerald JM, Bleecker ER, Nair P, et al. Lancet. 2016;388:2128–41. APPENDIX. Available from: href="https://www.sciencedirect.com/science/article/pii/S0140673616313228?via%3Dihub#sec1 (accessed March 2018).
  11. AstraZeneca plc, Data on File REF-BEN-027-DEC2017. December 2017. 
  12. AstraZeneca plc, Data on File REF-BEN-028-DEC2017. Dec ember 2017.
  13. Cloutier MM, Schatz M, Castro M, et al. J Allergy Clin Immunol. 2012;129(30):S24–S33.
  14. Santanello NC, Zhang J, Seidenberg B, et al. Eur Respir J. 1999;14:23–27.
  15. Juniper EF, Guyatt GH, Willan A, Griffith LE. J Clin Epidemiol. 1994;47(1):81–87.
  16. Windward Programme 2016. Available from : https://www.astrazeneca.com/media-centre/press-releases/2016/astrazeneca-announces-positive-results-from-benralizumab-phase-iii-programme-in-severe-asthma-17052016.html(accessed March 2018).
  17. Ferguson G, FitzGerald M, Bleecker E, et al. Lancet Respir Med. 2017;5(7):568–76.
  18. ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT02258542, BORA. Available from: https://www.clinicaltrials.gov/show/NCT02258542 (accessed March 2018).
  19. ClinicalTrials.gov. National Library of Medicine (US). Identifier NCT02417961, GREGALE. Available from: https://clinicaltrials.gov/ct2/show/NCT02417961(accessed March 2018).

Date of Preparation March 2018 GB-10258